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Abstract
Introduction: Increased expression of aggrecanase-1 (ADAMTS-4) has emerged as an important factor in
osteoarthritis (OA) and other joint diseases. This study aimed to determine whether the expression of ADAMTS-4 in
human chondrocytes is regulated by miRNA.
Methods: MiRNA targets were identified using bioinformatics. Chondrocytes were isolated from knee cartilage and
treated with interleukin-1 beta (IL-1b). Gene expression was quantified using TaqMan assays and protein
production was determined by immunoblotting. Luciferase reporter assay was used to verify interaction between
miRNA and target messenger RNA (mRNA).
Results: In silico analysis predicted putative target sequence of miR-125b on ADAMTS-4. MiR-125b was expressed
in both normal and OA chondrocytes, with significantly lower expression in OA chondrocytes than in normal
chondrocytes. Furthermore, IL-1b-induced upregulation of ADAMTS-4 was suppressed by overexpression of miR-
125b in human OA chondrocytes. In the luciferase reporter assay, mutation of the putative miR-125b binding site
in the ADAMTS-4 3’UTR abrogated the suppressive effect of miR125.
Conclusions: Our results indicate that miR-125b plays an important role in regulating the expression of ADAMTS-4
in human chondrocytes and this identifies miR-125b as a novel therapeutic target in OA.
Introduction
Osteoarthritis (OA) is the most common form of arthri-
tis and is characterized by loss of articular cartilage,
which is ascribed mainly to proteolysis of the structural
components of the extracellular matrix (ECM), that is,
proteoglycans and collagens. Collagen degradation is
principally carried out by several proteinases shedding
an ectodomain of membrane proteins belonging to the
matrix metalloproteinase (MMP) family, such as MMP1,
MMP8, and MMP13 [1-3]. On the other hand, aggreca-
nases represent another class of proteinases belonging
to the ADAMTS (a disintegrin and metalloproteinase
with thrombospondin motifs) family. Biochemical
studies indicate that ADAMTS 1, 4, 5, 8, 9, and 15 pos-
sess aggrecanase activity [4,5]. Song et al. [6] reported
that knockdown of aggrecanase-1 (ADAMTS-4), aggre-
canase-2 (ADAMTS-5), or both enzymes by small inter-
fering RNA attenuates the degradation of aggrecan in
human cartilage stimulated by a combination of both
tumor necrosis factor-alpha (TNF-a) and oncostatin M.
This suggests that both ADAMTS-4 and ADAMTS-5
contribute to aggrecanolysis in human tissue. Recent
studies showed that ADAMTS-4 is selectively overex-
pressed in human OA cartilage, with a positive correla-
tion with the degree of cartilage destruction, whereas
ADAMTS-5 is similarly expressed in both normal and
OA cartilages [7]. These results suggest that ADAMTS-
4 is a major aggrecanase in human OA cartilage and its
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Proinflammatory cytokines secreted from chondro-
cytes such as interleukin-1 beta (IL-1b) and TNF-a con-
tribute to the progression of OA [8-10]. IL-1b induces a
cascade of inflammatory and catabolic events in chon-
drocytes. It also changes chondrocyte anabolism by sup-
pressing the synthesis of proteoglycans and collagens
[9,11-13].
MicroRNAs (miRNAs), which belong to a class of
short 19 to 23 nucleotide non-coding RNAs, function as
posttranscriptional negative regulators by promoting
messenger RNA (mRNA) degradation or repressing
translation through complementarily binding target
sequences in the 3’-untranslated regions (3’-UTRs) of
specific mRNA targets [14-17]. Degradation of target
mRNAs depends on near-perfect complementarity while
for repression of translation partial complementarity is
sufficient [18].
Recent studies have identified the miRNA expression
profiles in human OA chondrocytes [19,20], but no con-
sensus on a specific miRNA being the regulator of
ADAMTS-4 expression has been reached. In this study,
we use bioinformatics to predict putative target
sequences for miR-125a, miR-125b and miR-4319 in
human ADAMTS-4 mRNA. We demonstrate that
expression of miR-125b, but not miR-125a and miR-
4319, is significantly decreased in human OA chondro-
cytes compared to normal chondrocytes. This prompted
us to validate whether ADAMTS-4 is regulated by miR-
125b in human OA chondrocytes. We also established a
reporter system using the 3’-UTR of human ADAMTS4
mRNA, and showed that this is targeted by miR-125b.
Materials and methods
Specimen selection
Cartilage tissues were aseptically obtained at the time of
total knee replacement from OA patients diagnosed
according to the American College of Rheumatology cri-
teria for this disease. The patients with Kellgren-Lawr-
ence OA grades II, III, and IV included five females and
two males, with a mean age of 74.1 years (ranging from
68 to 82 years). Articular cartilage from the weight-bear-
ing, fibrillated areas of the femoral condyle and tibial
plateau was cut into small pieces with a scalpel. Carti-
lage samples were minced and digested at 37°C with
trypsin-EDTA solution for 30 min, incubated with 3
mg/ml type II collagenase (Worthington Biochemical
Co, Lakewood, NJ, USA) in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco-BRL, Life Technologies, Merel-
beke, Belgium) for 18 h, filtered through a nylon mesh,
and washed extensively. Next, the isolated chondrocytes
were seeded in 75 cm2 culture flasks and incubated in
DMEM containing 10% fetal bovine serum (FBS), peni-
cillin (100 U/ml), and streptomycin (100 mg/ml) at 37°C
in an atmosphere of 5% CO2. At confluence, the cells
were detached and seeded in 12-well plates at a density
of 2×105/well. These experiments were performed in
accordance with a protocol approved by the Ethics
Committee of Nagoya University and all patients gave
written consent for the use of their tissues for this
research. Normal human articular chondrocytes from
knee joints including three males, with a mean age of
37.6 years (ranging from 34 to 45) were purchased from
Takara Bio Inc. (Shiga, Japan). Cartilage tissues for the
direct isolation of microRNA, were harvested from
human knee joints including three male, with a mean
age of 18.3 years (ranging from 17 to 19) for normal
samples (OA grade I), one male and two females, with a
mean age of 57.7 years (ranging from 54 to 65) for OA
samples (OA grade IV) and two male and one female,
with a mean age of 50.7 years (ranging from 47 to 55)
for normal age-matched (aging) samples (OA grade I),
which were obtained from the tissue banks with
approval of the Scripps Human Subjects Committee.
Joints were processed within 72 hours postmortem.
Cell culture
Articular cartilage tissues were cut into small pieces less
than 1 mm3, and subsequently digested with 1 mg/mL
collagenase from Clostridium histolyticum (Sigma-
Aldrich Co., Tokyo, Japan) at 37°C for 16 h with shak-
ing. Isolated primary cultured human OA articular
chondrocytes and 293T cells were cultured in DMEM
containing 10% FBS and 1% penicillin/streptomycin
(Gibco-BRL, Life Technologies, Grand Island, NY, USA)
at 37°C in a humidified atmosphere of 5% CO2. The
medium was changed every three days.
Treatment with IL-1b and preparation of miRNA
Primary cultured human chondrocytes were serum-
starved overnight and then treated with recombinant
human IL-1b (5 ng/mL; PeproTech, Rocky Hill, NJ,
USA) for the indicated periods of time. Total RNA con-
taining miRNA was extracted using the mirVana
miRNA isolation kit (Applied Biosystems, Life Technol-
ogies, Carlsbad, CA, USA). Cells were collected by
Lysis/Binding Buffer including 1/10 volume of miRNA
Homogenate Additive and then Acid-Phenol:Chloroform
was added. After centrifugation, the aqueous phase was
transferred to fresh tubes and, after addition of 1.25
volumes of 100% ethanol, applied to a filter cartridge.
After washing the filter, total RNA was extracted with
nuclease-free water. Total RNA of cartilage tissue was
isolated from fresh-frozen cartilage by homogenizing the
tissue in a freezer mill (Spex, Metuchen, NJ, USA) and
extracting the homogenate in TRIzol (Invitrogen, Life
Technologies, Carlsbad, CA, USA).
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Transfection
MiRNA precursor (pre-miR-125b), antagomir (anti-miR-
125b), or negative control oligonucleotides were
obtained from Applied Biosystems. Primary cultured
human chondrocytes were transfected with each oligo-
nucleotides using Lipofectamine 2000 (Invitrogen, Life
Technologies). Forty-eight hours after transfection, the
cells were serum-starved overnight and then cultured in
serum-free DMEM in the presence or absence of recom-
binant human IL-1b (5 ng/mL; PeproTech) for 24 hours.
Cells were harvested and subjected to total RNA and
protein extraction. HEK 293T cells were transfected
with 1 μg reporter plasmid, 1 μg effector plasmid or
point mutant of pre-miR-125b plasmid or negative con-
trol plasmid, and 10 ng of Renilla luciferase control vec-
tor using FuGENE HD Transfection Reagent (Promega,
Madison, WI, USA) in 24-well plates. The detail of all
constructs is described in ‘Luciferase reporter assay’.
Reverse transcription
Total RNA concentration was determined using absorp-
tion spectrochemical analysis. Ten nanograms of total
RNA containing miRNA from control and experimental
samples were reverse-transcribed using miR-125b stem-
loop RT primer, 10× RT buffer, 100 mM deoxynucleo-
side triphosphates (dNTPs), 50 units of MultiScribe
reverse transcriptase, and 20 units of RNase inhibitor at
16°C for 30 min, 42°C for 30 min, and 85°C for 5 min,
and then the miRNA product was maintained at 4°C.
Complementary DNA (cDNA) was produced using a
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Reverse transcription of cDNA from con-
trol and experimental samples was performed in 2 μL of
10× Reverse Transcription Buffer, 0.8 μL of 25× dNTP,
2 μL of 10× Random Primers, 1 μL of 50 units of Multi-
Scribe Reverse Transcriptase, and 1 μL of RNase inhibi-
tor at 25°C for 10 min, 37°C for 120 min, and 85°C for
5 s, and then the cDNA product was maintained at 4°C.
Quantitative RT-PCR analysis of ADAMTS-4, ADAMTS-5,
and miR-125b
Expression of ADAMTS-4, ADAMTS-5, glyceraldehyde
3-phosphate dehydrogenase (GAPDH) mRNA, mature
miR-125a, miR-125b, miR-4319 or U6 small nuclear
RNA (RNU6B) was determined using the TaqMan Gene
Expression Assay (Applied Biosystems). The reactions
for miRNA were performed in 20 μL of final volume
containing 1.33 μL of RT product, 10 μL of 2× TaqMan
Universal Master Mix, 1 μL of 20× Custom TaqMan
Small RNA Assay, and 7.67 μL of nuclease-free water.
The reactions for mRNA were performed in 20 μL of
final volume containing 9 μL of RT product, 10 μL of
2× TaqMan Universal Master Mix, and 1 μL of 20×
TaqMan Assay. To reduce variability among replicates,
PCR premixes, which contain all reagents except for the
template, were prepared and aliquotted into 0.2 ml thin
well plates. The samples were incubated at 95°C for 10
min, followed by 40 cycles at 95°C for 30 s and 60°C for
1 min. Expression of GAPDH and RNU6B were used as
internal controls to normalize each mRNA and miRNA
expression, respectively. A threshold cycle was observed
in the exponential phase of amplification, and quantifi-
cation of relative expression levels was determined by
the ΔΔCt method. The value of each control sample was
set at 1 and was used to calculate the fold change in tar-
get genes.
Immunoblotting
Cell lysates were prepared using RIPA buffer (sc-24948;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), sub-
jected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), and then transferred to
nitrocellulose membranes (Bio-Rad, Hercules, CA,
USA). Membranes were blocked with 5% nonfat dry
milk in Tris-buffered saline containing 0.1% Tween 20
and then treated with diluted (1:1,000) polyclonal anti-
bodies specific for ADAMTS-4 (Cosmo Bio Co. Ltd.,
Tokyo, Japan) or b actin (Cell Signaling Technology,
Danvers, MA, USA). Immunoreactive proteins were
visualized using horseradish peroxidase-conjugated sec-
ondary antibodies and enhanced chemiluminescence
(Thermo Scientific, Tokyo, Japan). Images were captured
using AE-9150 Ez-Capture II (Atto, Tokyo, Japan) and
analyzed using CS Analyzer version 3.0 (Atto). Each
band was scanned with background correction, and
values were averaged and expressed as the mean ± stan-
dard deviation (SD).
Luciferase reporter assay
The luciferase Vector pLuc2 was used to construct a
reporter plasmid containing 1,389 base pairs of the
3’-UTR of human ADAMTS-4 mRNA (uc001fyu.2
obtained from UCSC genome browser [21]) containing
two parts of the predicted complementary seed
sequence for miR-125b (sequence of mature form: UCC-
CUGAGACCCUAACUUGUGA). Total RNA (1 μg)
from human chondrocytes was reverse-transcribed into




CAC). PCR products and vectors were digested with
EcoRV and Kpn I restriction endonucleases (New Eng-
land Biolabs, Ipswich, MA, USA), digested vectors were
dephosphorylated by calf intestinal phosphatase (CIP)
and ligated 3′ to the luciferase reporter gene using the
EcoRV and Kpn I site to generate pLuc2-ADAMTS-4
plasmid (reporter plasmid). We found two putative miR-
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125b sequences in the human genome, termed pre-miR-
125b-1 (encoded on chromosomes 11) (uc010rzr.1) and
pre-miR-125b-2 (encoded on chromosomes 21)
(uc002ykf.3), respectively. Genomic sequences contain-
ing precursors of miR-125b were amplified from DNA








Each pre-miR cassette was digested with BamH I and
EcoRV restriction endonucleases (New England Biolabs).
Digested vectors were dephosphorylated by CIP and
ligated into the pcDNA3.1 vector using the BamH I and
EcoRV site to generate pcDNA3.1-pre-miR-125b-1 or -2
plasmid (effector plasmid). Using site-directed mutagen-
esis, we inserted several mutations into the seed
sequence of miR-125b-1, miR125b-2 and ADAMTS-4
3′-UTR. Mutated vectors of miR-125b precursors were
amplified from each effector plasmid template using pri-


















TGTGATGTTACTAAAATACCT; the bold letters indi-
cate mutations. the uppercase letters indicate comple-
mentary binding in the precursor). Mutated vectors of
ADAMTS-4 3′-UTR were amplified from reporter plas-




TTGAC, ADAMTS-4 3′-UTR point mutation 2 For-
ward; GAACTCCTGACCAGaCCtaATCGACCTGCCT
and Reverse; AGGCAGGTCGATTAGGTCTGGTCAG-
GAGTTC; the bold letters indicate mutations. the
uppercase letters indicate complementary binding in the
ADAMTS-4 3′-UTR). After DpnI digestion, digested vec-
tors were transformed, and then single colonies were
picked from ampicillin agar plates, and plasmid DNA was
prepared using a Plasmid Miniprep Kit (Qiagen, Valencia,
CA, USA). Finally, we confirmed the sequence of estab-
lished constructs as described above. The luciferase activ-
ity assay was performed 24 hours after transfection, using
the Dual-Luciferase Reporter Assay System (Promega)
and a VICTOR X Light Luminescence Plate Reader (Per-
kinElmer, Waltham, MA, USA). Firefly luciferase activity
was normalized to Renilla luciferase activity. Each experi-
ment was performed three times in triplicate
Statistical analysis
All data were obtained from at least three independent
experiments performed in triplicate. Statistical signifi-
cance was determined using Student’s t test. P values
less than 0.05 were considered significant, and P values
less than 0.001 were considered highly significant.
Results
Prediction of three miRNA target sequences in the 3’-UTR
of human ADAMTS-4 mRNA
We used TargetScan 6.2 [22] to identify the miRNAs
that target ADAMTS-4 mRNA. TargetScan 6.2 identi-
fied a sequence conserved in the 3’-UTR of ADAMTS-4
mRNA that was complementary to the miR-125b (Fig-
ure 1A), miR-125a and miR-4319 seed sequences (data
not shown). We hypothesized that any of these miRNAs,
if expressed in human chondrocytes may play an impor-
tant role in regulating ADAMTS-4 expression.
MiR-125b expression in normal and OA chondrocytes
We determined the expression of miR-125b, miR-125a
and miR-4319 using quantitative real-time PCR in normal
and OA chondrocytes and cartilage tissues. In normal
chondrocytes, miR-125b was strongly expressed while
miR-125a and -4319 were barely detectable (Figure 1B).
The expression of miR-125b was 49-fold higher than
miR-125a and approximately two million-fold higher
than miR-4319 (Figure 1B). Expression of miR-125b, but
not miR-125a and -4319, was found to be 54% lower in
OA chondrocytes compared to normal chondrocytes
(Figure 1C and data not shown). Compared to young
normal cartilage tissue samples (mean age = 18.3 years),
the expression of miR-125b was 21% lower in normal
cartilage tissue samples from older donors (mean age =
50.7 years) and 85% lower in age-matched OA cartilage
tissue samples (mean age = 57.7 years) (Figure 1C).
IL-1b induces ADAMTS-4 expression and suppresses
miR-125b expression
We examined whether IL-1b affects the expression
of ADAMTS-4, ADAMTS-5 and miR-125b. IL-1b
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Figure 1 Presence of miR-125b target sequence in the 3′-UTR of human ADAMTS-4 mRNA and its expression in primary cultured
human chondrocytes and human cartilage tissues. (A) TargetScan 6.2 predicted duplex of hsa-miR-125b seed sequence with target
sequence in the 3’-UTR of human ADAMTS-4 mRNA. (B) Relative expression of miR-125b, miR125a and miR-4319 in normal chondrocytes (n = 3)
and each threshold cycle (Ct) values from real-time PCR. (C) Relative expression of miR-125b in normal and osteoarthritic (OA) chondrocytes and
normal, aging and OA cartilage tissue samples (n = 3 for normal chondrocytes normal, aging and OA cartilage from three different donors, n =
7 for OA chondrocytes from seven different donors). The data are expressed as mean and SEM of three independent experiments, each of which
was run in triplicate. ** = P <0.001 as measured using an unpaired Student’s t test. ADAMTS-4, aggrecanase-1; PCR, polymerase chain reaction;
SEM, standard error of the mean; 3’-UTR, 3’-untranslated region.
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treatment suppressed miR-125b expression at 12 and 24
h in normal chondrocytes and at 6,12 and 24 h in OA
chondrocytes (P <0.001) (Figure 2A). IL-1b treatment
induced ADAMTS-4 expression in a time-dependent
manner in both normal and OA chondrocytes (P
<0.001). ADAMTS-5 mRNA expression was also
increased in a time-dependent manner, but the magni-
tude of induction was much lower than for ADAMTS-4
mRNA (Figure 2B).
Regulation of ADAMTS4 mRNA expression by miR-125b
in human chondrocytes
To examine whether miR-125b regulates ADAMTS-4 in
human normal and OA chondrocytes, we transfected the
cells with pre-miR-125b or anti-miR-125b and treated
with IL-1b. Significant induction of miR-125b was
observed in cells transfected with pre-miR-125b compared
to negative control (P <0.001), and suppression of miR-
125b was observed in cells transfected with anti-miR-125b
Figure 2 IL-1b induces ADAMTS-4 expression and suppresses miR-125b expression. (A) Relative expression of miR-125b in normal (n = 3)
and osteoarthritic (OA) (n = 7) chondrocytes stimulated with IL-1b for 24 hours. (B) Kinetics of expression of mRNA of ADAMTS-4 and ADAMTS-
5 in normal (n = 3) and OA (n = 7) chondrocytes treated with IL-1b for 6, 12 and 24 hours. The data are expressed as mean and SEM of three
independent experiments, each of which was run in triplicate. ** = P <0.001 as measured using an unpaired Student’s t test. ADAMTS-4,
aggrecanase-1; SEM, standard error of the mean.
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compared to negative control (P <0.001) (Figure 3A). MiR-
125b decreased IL-1b-induced ADAMTS-4 mRNA (P
<0.001) (Figure 3B). On the other hand, anti-miR-125b
increased IL-1b-induced ADAMTS-4 mRNA (P <0.05)
(Figure 3B).
Regulation of ADAMTS-4 protein by miR-125b in human
chondrocytes
To examine whether miR-125b also regulates ADAMTS-
4 protein levels, we performed western blotting on lysates
from human OA chondrocytes transfected with miR-
125b with or without IL-1b. In response to IL-1b,
ADAMTS-4 protein was increased (Figure 4A). In cells
transfected with miR-125b, ADAMTS-4 protein was
reduced by approximately 62% compared to cells trans-
fected with control miRNA (P <0.05) (Figure 4B and C).
Functional validation of miR-125b using ADAMTS-4
3’-UTR luciferase reporter system
To confirm that miR-125b regulates ADAMTS-4 mRNA
via directly binding to the predicted target sequence, we
established a reporter system by combining luciferase
Figure 3 Modulation of miR-125b affects ADAMTS-4 expression in OA chondrocytes. (A) Relative expression level of miR-125b in human
osteoarthritic (OA) chondrocytes transfected with pre-miR-125b, anti-miR-125b or negative control (n = 5). (B) Relative expression level of
ADAMTS-4 mRNA 24 hours after IL-1b treatment in normal (n = 3) and OA (n = 5) chondrocytes transfected with pre-miR-125b, anti-miR-125b or
negative control. The data are expressed as mean and SEM of three independent experiments, each of which was run in triplicate. ** = P <0.001,
* = P <0.05 as measured using an unpaired Student’s t test. ADAMTS-4, aggrecanase-1; anti-miR-125b, MiRNA-125b antagomir; pre-miR-125b
MiRNA-125b precursor; SEM, standard error of the mean
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and the 3’-UTR of human ADAMTS-4 mRNA. As we
identified two putative precursors of miR-125b as
described in Materials and Methods, we validated both
in this assay. Significant induction of miR-125b was con-
firmed in cells transfected with two putative precursors
of miR-125b compared to negative control (P <0.001)
(Figure 5A). Compared to chondrocytes, 293T cells
express very low levels of miR-125b (Figure 5B). We
transiently co-transfected the ADAMTS-4 3’-UTR
reporter construct or mutant reporter construct, and
each pre-miR-125b or each mutant construct. The over-
expression of miR-125b-1 or -2 markedly reduced luci-
ferase activity compared to controls (P <0.001) (Figure
5C). We further confirmed these findings by using
mutated forms of the 3’-UTR of human ADAMTS-4
mRNA and each miR-125b precursor. Transfection with
the mutants abolished the suppression of luciferase
activity (Figure 5C). These results indicate that
suppression is due to direct miR-125b binding to com-
plementary seed sequence in ADAMTS-4 3’-UTR.
Discussion
In this study, we for the first time identified comple-
mentary sequence to miR-125b seed sequence in 3’-
UTR of human ADAMTS-4 mRNA. Our results show
that miR-125b but not miR-125a is strongly expressed
in normal human chondrocytes and cartilage tissues.
Both miR-125a and miR-125b were previously reported
to be highly expressed in mouse spinal cord and liver,
but only miR-125b was detected in other tissues [23]. In
humans, there are two miR-125b gene loci: miR-125b-1
on chromosome 11q23 and miR-125b-2 on chromo-
some 21q21, which are differentially expressed in a tis-
sue-specific pattern. Although their pre-microRNAs
have slightly different sequences, their mature sequences
are identical [24].
Figure 4 MiR-125b suppresses ADAMTS-4 protein in OA chondrocytes. (A) Increased production of ADAMTS-4 protein 24 hours after IL-1b
treatment. (B) Osteoarthritic (OA) chondrocytes transfected with miR-125b or negative control incubated with or without IL-1b for 24 hours. (C)
Bar graphs represent the average-fold increase ± SD in pixel intensity of bands representing ADAMTS-4 normalized to b actin, obtained from five
separate western blot analyses for each cell condition. * = P <0.05 as measured using an unpaired Student’s t test. ADAMTS-4, aggrecanase-1; IL-
1 b, interleukin-1 beta; SD, standard deviation.
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Figure 5 Functional validation of miR-125b binding the putative target sequence in the 3′-UTR of ADAMTS-4 mRNA. (A) Relative
expression level of miR-125b in HEK293T cells transfected with pcDNA3.1-pre-miR-125b-1, -2 or negative control (n = 3). (B) Relative expression
of miR-125b in 293T cells and normal chondrocytes (n = 3). (C) Luciferase activity in 293T cells co-transfected with pLuc2-ADAMTS-4 3’-UTR or
-ADAMTS-4 3’-UTR mutant and pcDNA3.1-pre-miR-125b-1, -2, -125b-1 mutant, -125b-2 mutant or pcDNA3.1 (n = 3). The data are expressed as
mean and SEM of three independent experiments, each of which was run in triplicate. ** = P <0.001 as measured using an unpaired Student’s
t test. ADAMTS-4, aggrecanase-1; pre-miR-125b MiRNA-125b precursor; SEM, standard error of the mean; 3’-UTR, 3’-untranslated region.
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The present findings demonstrate that ADAMTS-4 is
indeed regulated by miR-125b via direct binding the pre-
dicted target sequence, resulting in suppression of
ADAMTS-4 at both mRNA and protein level. The poten-
tial interaction between miR-125b and human ADAMTS-
4 mRNA was confirmed using luciferase reporter assay.
In general, an 8 base-pair match is considered to repre-
sent a full-match seed sequence. For miR-125b and
ADAMTS4 there is a 7 base-pair match, indicating partial
complementarity. Computational and experimental evi-
dence indicates that miRNA target sites with as little as 7
base pairs of complementarity to the miRNA 5’ end are
sufficient to confer regulation in vivo [25].
IL-1b is an important regulator of joint inflammation
and cartilage degradation in OA and the present find-
ings provide a link between IL-1b and miR-125b as
chondrocyte treatment with IL-1b suppresses miR-125b
expression, while inducing ADAMTS-4 expression. IL-
1b has also been reported to induce ADAMTS-4 mRNA
levels with a dependency on NF-B signaling [26]. In
addition to this pathway, miR-125b might be another
factor to regulate ADAMTS-4 mRNA expression in
response to IL-1b signaling. Furthermore, we demon-
strated that in primary human OA chondrocytes, over-
expression of miR-125b leads to a significant reduction
in IL-1b- induced ADAMTS-4 production. Collectively,
the results indicate that miR-125b directly regulates
ADAMTS-4 in the context of activation by IL-1b as a
key mediator of OA pathogenesis.
In this study, miR-125 suppressed ADAMTS-4 mRNA
expression by 72% and protein production by 62% fol-
lowing IL-1b stimulation. In our previous study, miR-
140 suppressed ADAMTS-5 mRNA expression by simi-
lar degree with IL-1b stimulation [27]. It thus appears
that the two main aggrecanases in cartilage are regulated
by different miRNAs.
We also predicted target sequence of miR-125a and
miR-4319 in 3’-UTR ADAMTS-4 mRNA. However, our
results indicate that miR-125a and miR-4319 expression
in chondrocytes is very low compared to miR-125b and
there are no significant changes in OA chondrocytes
(data not shown). Thus, miR-125b, but not miR-125a and
miR-4319, may play a role in OA development. The
expression of miR-125b was reduced with a dependency
on age, but the expression of miR-125b more significantly
decreased in age-matched OA cartilage tissues compared
to young normal cartilage tissues. The expression of miR-
125b seems to be influenced by age-related factors, but
more strongly by mechanisms related to OA.
The protective role of miR-125b in cartilage may
extend beyond the suppression of ADAMTS-4. In other
cell types miR-125b also suppressed MMP-13 and vas-
cular endothelial cadherin [28,29]. MMP-13 is an impor-
tant collagenase in articular cartilage [30], and vascular
endothelial cadherin regulates angiogenesis, which is
increased in OA-affected joints [31].
Conclusions
This is the first report identifying a miRNA, miR-125b,
as a posttranscriptional regulator of ADAMTS-4 in
human chondrocytes. We have demonstrated the two
precursors of miR-125b in human genome suppress the
expression of ADAMTS-4 mRNA and protein. We sug-
gest that to controlling the expression of miR-125b has
potential as a novel approach for prevention and treat-
ment of OA.
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